Hepatocellualar carcinoma serum markers

Seminars in Oncology

Volumn 39, Issue 4, 2012, Pages 410-433

  Bertino, Gaetano ^a   Ardiri, Annalisa ^a   Malaguarnera, Michele ^a   Malaguarnera, Giulia ^a   Bertino, Nicoletta ^a   Calvagno, Giuseppe Stefano ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLUTININ; ALPHA CATENIN; ALPHA FETOPROTEIN; ALPHA LEVO FUCOSIDASE; CHROMOGRANIN A; DECARBOXYPROTHROMBIN; EPIDERMAL GROWTH FACTOR RECEPTOR; F ACTIN; GELATINASE A; GLYPICAN 3; IMMUNOGLOBULIN M; LENS CULINARIS AGGLUTININ; LOW DENSITY LIPOPROTEIN; OSTEOPONTIN; SCATTER FACTOR; SOMATOMEDIN; SOMATOMEDIN B; SQUAMOUS CELL CARCINOMA ANTIGEN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; WNT PROTEIN;

ANGIOGENESIS; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CARBOXYLATION; CELL MOTILITY; CELL PROLIFERATION; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENDOCYTOSIS; GENE EXPRESSION; HUMAN; IMMUNOLOCALIZATION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR VOLUME;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; GLYPICANS; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84864459298     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.05.001     Document Type: Conference Paper

References (211)

1. H.B. El-Serag, K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2007 2557 2576
2. D.M. Parkin Global cancer statistics in the year 2000 Lancet Oncol 2 2001 533 543
3. K.A. McGlynn, L. Tsao, A.W. Hsing, S.S. Devesa, J.F. Fraumeni Jr International trends and patterns of primary liver cancer Int J Cancer 94 2001 290 296
4. G.D. Kirk, O.A. Lesi, M. Mendy The Gambia Liver Cancer Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa Hepatology 39 2004 211 219
5. T. Umemura, K. Kiyosawa Epidemiology of hepatocellular carcinoma in Japan Hepatol Res 37 Suppl 2 2007 S95 S100
6. H.B. El-Serag, A.C. Mason Rising incidence of hepatocellular carcinoma in the United States N Engl J Med 340 1999 745 750
7. K. Okuda Hepatocellular carcinoma J Hepatol 32 1 Suppl 2000 225 237
8. J. Bruix, M. Sherman, J.M. Llovet Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
9. A.S. Befeler, A.M. Di Bisceglie Hepatocellular carcinoma: diagnosis and treatment Gastroenterology 122 2002 1609 1619
10. J.M. Llovet, A. Burroughs, J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
11. J.M. Llovet, J. Fuster, J. Bruix The Barcelona approach: diagnosis, staging, and treatmentof hepatocellular carcinoma Liver Transpl 10 2 Suppl 1 2004 S115 S120
12. K. Kiyosawa, T. Umemura, T. Ichijo, A. Matsumoto, K. Yoshizawa, A. Gad, E. Tanaka Hepatocellular carcinoma: recent trends in Japan Gastroenterology 127 5 Suppl 1 2004 S17 S26
13. H.B. El-Serag Hepatocellular carcinoma: recent trends in the United States Gastroenterology 127 5 Suppl 1 2004 S27 S34
14. G. Fattovich, T. Stroffolini, I. Zagni, F. Donato Hepatocellular carcinoma in cirrhosis: incidence and risk factors Gastroenterology 127 5 Suppl 1 2004 S35 S50
15. H.E. Blum Hepatocellular carcinoma: therapy and prevention World J Gastroenterol 11 2005 7391 7400
16. A.M. Di Bisceglie Screening for hepatocellular carcinoma: being old is not all bad Am J Gastroenterol 99 2004 1477 1478
17. J.A. Talwalkar, G.J. Gores Diagnosis and staging of hepatocellular carcinoma Gastroenterology 127 5 Suppl 1 2004 S126 S132
18. H.C. Spangenberg, R. Thimme, H.E. Blum Serum markers of hepatocellular carcinoma Semin Liver Dis 26 2006 385 390
19. M.L. Volk, J.C. Hernandez, G.L. Su, A.S. Lok, J.A. Marrero Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFPL3 Cancer Biomark 3 2007 79 87
20. P. Pontisso, S. Quarta, C. Caberlotto Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma Int J Cancer 119 2006 735 740
21. G. Bertino, S. Neri, C.M. Bruno Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma Minerva Med 102 2011 363 371
22. A.A. Terentiev, N.T. Moldogazieva Structural and functional mapping of alpha-fetoprotein Biochemistry 71 2006 120 132
23. G.J. Mizejewski Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy Expert Rev Anticancer Ther 2 2002 709 735
24. R. Saffroy, P. Pham, M. Reffas, M. Takka, A. Lemoine, B. Debuire New perspectives and strategy research biomarkers for hepatocellular carcinoma Clin Chem Lab Med 45 2007 1169 1179
25. J. Bruix, M. Sherman, J.M. Llovet Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver J Hepatol 35 2001 421 430
26. S.J. Han, S. Yoo, S.H. Choi, E.H. Hwang Actual half-life of alphafetoprotein as a prognostic tool in pediatric malignant tumors Pediatr Surg Int 12 1997 599 602
27. P. Li, S.S. Wang, H. Liu, N. Li, M.A. McNutt, G. Li, H.G. Ding Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma World J Gastroenterol 17 2011 4563 4571
28. H. Oka, A. Saito, K. Ito Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein J Gastroenterol Hepatol 16 2001 1378 1383
29. Y. Sato, K. Nakata, Y. Kato Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein N Engl J Med 328 1993 1802 1806
30. H. Miyaaki, O. Nakashima, M. Kurogi, K. Eguchi, M. Kojiro Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma J Gastroenterol 42 2007 962 968
31. Y. Aoyagi, Y. Suzuki, M. Isemura The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma Cancer 61 1988 769 774
32. K. Taketa Alpha-fetoprotein: reevaluation in hepatology Hepatology 12 1990 1420 1432
33. T. Sassa, T. Kumada, S. Nakano, T. Uematsu Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma Eur J Gastroenterol Hepatol 11 1999 1387 1392
34. F. Yamashita, M. Tanaka, S. Satomura, K. Tanikawa Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas Gastroenterology 111 1996 996 1001
35. R. Kuromatsu, M. Tanaka, K. Tanikawa Serum alpha-fetoprotein and lens culinaris agglutinin-reactive fraction of alpha-fetoprotein in patients with hepatocellular carcinoma Liver 13 1993 177 182
36. K. Hayashi, T. Kumada, S. Nakano Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alphafetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma Am J Gastroenterol 94 1999 3028 3033
37. F. Yamashita, M. Tanaka, S. Satomura, K. Tanikawa Monitoring of lectin-reactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transcatheter arterial embolization Eur J Gastroenterol Hepatol 7 1995 627 633
38. N. Yamashiki, T. Seki, M. Wakabayashi Usefulness of Lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein (AFP-L3) as a marker of distant metastasis from hepatocellular carcinoma Oncol Rep 6 1999 1229 1232
39. F. Yamashita, M. Tanaka, S. Satomura, K. Tanikawa Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinoma Gastroenterology 111 1996 996 1001
40. L.M. Wright, J.T. Kreikemeier, C.J. Fimmel A concise review of serum markers for hepatocellular cancer Cancer Detect Prev 31 2007 35 44
41. G. Bertino, A.M. Ardiri, P.M. Boemi A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma Panminerva Med 50 2008 221 226
42. B.I. Carr, F. Kanke, M. Wise, S. Satomura Clinical evaluation of lens culinaris agglutininreactive alpha-fetoprotein and des-gammacarboxy prothrombin in histologically proven hepatocellular carcinoma in the United States Dig Dis Sci 52 2007 776 782
43. M. Gotoh, T. Nakatani, T. Masuda Prediction of invasive activities in hepatocellular carcinomas with special reference to alphafetoprotein and des-gamma-carboxyprothrombin Jpn J Clin Oncol 33 2003 522 526
44. M. Kaibori, Y. Matsui, H. Yanagida, N. Yokoigawa, A.H. Kwon, Y. Kamiyama Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma World J Surg 28 2004 702 707
45. A. Leerapun, S.V. Suravarapu, J.P. Bida The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population Clin Gastroenterol Hepatol 5 2007 394 402
46. R. Saffroy, P. Pham, M. Reffas, M. Takka, A. Lemoine, B. Debuire New perspectives and strategy research biomarkers for hepatocellular carcinoma Clin Chem Lab Med 45 2007 1169 1179
47. K. Murata, A. Sakamoto Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des gamma-carboxy prothrombin production in hepatocellular carcinoma Int J Oncol 33 2008 1149 1155
48. K. Murata, H. Suzuki, H. Okano, T. Oyamada, Y. Yasuda, A. Sakamoto Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des gamma-carboxy prothrombin production in hepatocellular carcinoma Int J Oncol 35 2009 1005 1014
49. J. Bruix, M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
50. F. Trevisani, N.S. De, G. Rapaccini Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience) Am J Gastroenterol 97 2002 734 744
51. B. Zhang, B. Yang Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer J Med Screen 6 1999 108 110
52. L. Bolondi, S. Sofia, S. Siringo Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis Gut 48 2001 251 259
53. J. Collier, M. Sherman Screening for hepatocellular carcinoma Hepatology 27 1998 273 278
54. F. Trevisani, P.E. D'Intino, A.M. Morselli-Labate Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status J Hepatol 34 2001 570 575
55. M. Sherman, K.M. Peltekian, C. Lee Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population Hepatology 22 1995 432 438
56. F. Trevisani, P.E. D'Intino, P. Caraceni Etiologic factors and clinical presentation of hepatocellular carcinoma Differences between cirrhotic and noncirrhotic Italian patients Cancer 75 1995 2220 2232
57. N. Bayati, A.L. Silverman, S.C. Gordon Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C Am J Gastroenterol 93 1998 2452 2456
58. A.V. Franca, J. Elias Jr, B.L. Lima, A.L. Martinelli, F.J. Carrilho Diagnosis, staging and treatment of hepatocellular carcinoma Braz J Med Biol Res 37 2004 1689 1705
59. M.F. Yuen, C.L. Lai Serological markers of liver cancer Best Pract Res Clin Gastroenterol 19 2005 91 99
60. F. Grizzi, B. Franceschini, C. Hamrick, E.E. Frezza, E. Cobos, M. Chiriva-Internati Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma J Transl Med 5 2007 3
61. D. Semela, J.F. Dufour Angiogenesis and hepatocellular carcinoma J Hepatol 41 2004 864 880
62. I.C. Weitz, H.A. Liebman Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review Hepatology 18 1993 990 997
63. S. Nakamura, K. Nouso, K. Sakaguchi Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size Am J Gastroenterol 101 2006 2038 2043
64. Y.H. Baek, J.H. Lee, J.S. Jang Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP Hepatogastroenterology 56 2009 763 767
65. A.S. Lok, R.K. Sterling, J.E. Everhart Des-gamma-carboxy prothrombin and alphafetoprotein as biomarkers for the early detection of hepatocellular carcinoma Gastroenterology 138 2010 493 502
66. K. Yamamoto, H. Imamura, Y. Matsuyama Significance of alpha-fetoprotein and desgamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy Ann Surg Oncol 16 2009 2795 2804
67. H. Miyaaki, O. Nakashima, M. Kurogi, K. Eguchi, M. Kojiro Lens culinaris agglutininreactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma J Gastroenterol 42 2007 962 968
68. S. Hagiwara, M. Kudo, T. Kawasaki Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma J Gastroenterol 41 2006 1214 1219
69. K. Shirabe, S. Itoh, T. Yoshizumi The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma - with special reference to the serum levels of des-gamma-carboxy prothrombin J Surg Oncol 95 2007 235 240
70. M. Sakon, M. Monden, M. Gotoh Relationship between pathologic prognostic factors and abnormal levels of des-gamma-carboxyprothrombin and alpha-fetoprotein in hepatocellular carcinoma Am J Surg 163 1992 251 256
71. G.L. Grazi, A. Mazziotti, C. Legnani The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin Liver Transpl Surg 1 1995 249 255
72. T. Suehiro, T. Matsumata, H. Itasaka, A. Taketomi, K. Yamamoto, K. Sugimachi Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma Surgery 117 1995 682 691
73. H. Sugimoto, S. Takeda, S. Inoue, T. Kaneko, K. Watanabe, A. Nakao Des-gamma-carboxy prothrombin (DCP) ratio, a novel parameter measured by monoclonal antibodies MU-3 and 19B7, as a new prognostic indicator for hepatocellular carcinoma Liver Int 23 2003 38 44
74. M. Shimada, Y. Yonemura, H. Ijichi Living donor liver transplantation for hepatocellular carcinoma: a special reference to a preoperativedes-gamma- carboxy prothrombin value Transplant Proc 37 2005 1177 1179
75. A. Nanashima, S. Morino, H. Yamaguchi Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma Eur J Surg Oncol 29 2003 735 742
76. H. Imamura, Y. Matsuyama, Y. Miyagawa Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma Br J Surg 86 1999 1032 1038
77. T. Kawakita, K. Shiraki, Y. Yamanaka A new prognostic scoring system involving desgamma- carboxy prothrombin as a useful marker for predicting prognosis in patients with hepatocellular carcinoma Int J Oncol 23 2003 1115 1120
78. K. Omagari, S. Honda, Y. Kadokawa Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma J Gastroenterol Hepatol 19 2004 805 811
79. H. Toyoda, T. Kumada, Y. Osaki Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers Clin Gastroenterol Hepatol 4 2006 1528 1536
80. S. Maeda, S. Fujiyama, M. Tanaka, H. Ashihara, R. Hirata, K. Tomita Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization Hepatol Res 23 2002 202 210
81. K. Hakamada, N. Kimura, T. Miura Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma World J Gastroenterol 14 2008 1370 1377
82. Y. Koike, Y. Shiratori, S. Sato Desgamma- carboxy prothrombin as a useful predisposing factor for the development of portalvenous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients Cancer 91 2001 561 569
83. H. Toyoda, T. Kumada, Y. Kaneoka Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinomaon survival after curative treatment of patients with HCC J Hepatol 49 2008 223 232
84. S. Takahashi, M. Kudo, H. Chung PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy Oncology 75 Suppl 1 2008 91 98
85. Y. Kim do, M.S. Choi, J.H. Lee Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization World J Gastroenterol 12 2006 6992 6997
86. M. Kobayashi, K. Ikeda, Y. Kawamura High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma Cancer 115 2009 571 580
87. A. Taketomi, K. Sanefuji, Y. Soejima Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation Transplantation 87 2009 531 537
88. M. Fujiki, Y. Takada, Y. Ogura Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma Am J Transplant 9 2009 2362 2371
89. Y. Harino, M. Fujii, S. Imura The role of des-gamma-carboxyprothrombin expression in hepatocellular carcinoma Hepatogastroenterology 55 2008 1385 1389
90. F.J. Gao, S.X. Cui, M.H. Chen Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells Life Sci 83 2008 815 820
91. S.B. Wang, Y.N. Cheng, S.X. Cui Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth andmigration Clin Exp Metastasis 26 2009 469 477
92. T. Fujikawa, H. Shiraha, K. Yamamoto Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma Acta Med Okayama 63 2009 299 304
93. S. Kitai, M. Kudo, Y. Minami A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score Intervirology 51 Suppl 1 2008 86 94
94. S. Kitai, M. Kudo, Y. Minami Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score Oncology 75 Suppl 1 2008 83 90
95. R.K. Sterling, L. Jeffers, F. Gordon Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des gammacarboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma Clin Gastroenterol Hepatol 7 2009 104 113
96. J. Seong, S.J. Shim, I.J. Lee, K.H. Han, C.Y. Chon, S.H. Ahn Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy Int J Radiat Oncol Biol Phys 67 2007 1037 1042
97. A. Nanashima, K. Omagari, Y. Sumida Evaluation of new prognostic staging systems (SLiDe score) for hepatocellular carcinoma patients who underwent hepatectomy Hepatogastroenterology 56 2009 1137 1140
98. G. Bertino, A.M. Ardiri, G.S. Calvagno, N. Bertino, P.M. Boemi Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer Drug News Perspect 23 2010 498 508
99. S. Fujiyama, M. Tanaka, S. Maeda Tumour markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma Oncology 62 2002 57 63
100. A. Toyosaka, E. Okamoto, M. Mitsunobu, T. Oriyama, N. Nakao, K. Miura Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel Am J Gastroenterol 91 1996 1610 1615
101. M. Mitsunobu, A. Toyosaka, T. Oriyama, E. Okamoto, N. Nakao Intrahepatic metastases in hepatocellular carcinoma: the role of the portal vein as an efferent vessel Clin Exp Metastasis 14 1996 520 529
102. M. Suzuki, H. Shiraha, T. Fujikawa Des-gamma-carboxyl prothrombin is a potential autologous growth factor for hepatocellular carcinoma J Biol Chem 280 2005 6409 6415
103. G. Malaguarnera, M. Giordano, I. Paladina, M. Berretta, A. Cappellani, M. Malaguarnera Serum markers of hepatocellular carcinoma Dig Dis Sci 55 2010 2744 2755
104. M. Bernfield, M. Gote, P.W. Park Functions of cell surface heparan sulfate proteoglycans Annu Rev Biochem 68 1999 729 777
105. J. Filmus, M. Capurro Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma Mol Diagn 8 2004 207 212
106. H.H. Song, W. Shi, J. Filmus OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2 J Biol Chem 272 1997 7574 7577
107. R. Reich-Slotky, D. Bonneh-Barkay, E. Shaoul, B. Bluma, C.M. Svahn, D. Ron Differential effect of cell-associated heparan sulfates on the binding of keratinocyte growth factor (KGF) and acidic fibroblast growth factor to the KGF receptor J Biol Chem 269 1994 32279 32285
108. G. Pilia, R.M. Hughes-Benzie, A. MacKenzie Mutations in GPC-3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome Nat Genet 12 1996 241
109. H.C. Hsue, W. Cheng, P.L. Lai Cloning and expression of a developmentally regulated transcripts MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution Cancer Res 57 1997 5179 5184
110. Z.W. Zhu, H. Friess, L. Wang Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders Gut 48 2001 558 564
111. Z.W. Zhu, H. Friess, L. Wang Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders Gut 48 2001 558 564
112. Y.K. Sung, S.Y. Hwang, M.K. Park Glypican-3 is overexpressed in human hepatocellular carcinoma Cancer Sci 94 2003 259 262
113. T. Nakatsura, Y. Yoshitake, S. Senju Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker Biochem Biophys Res Commun 306 2003 16 25
114. Y. Midorikawa, S. Ishikawa, H. Iwanari Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling Int J Cancer 103 2003 455 465
115. M. Capurro, I.R. Wanless, M. Sherman Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma Gastroenterology 125 2003 89 97
116. Y. Hippo, K. Watanabe, A. Watanabe Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma Cancer Res 64 2004 2418 2423
117. N. Yamauchi, A. Watanabe, M. Hishinuma The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma Mod Pathol 18 2005 1591 1598
118. M. Capurro, J. Filmus Glypican-3 as a serum marker for hepatocellular carcinoma Cancer Res 65 2005 372
119. M.I. Capurro, Y.Y. Xiang, C. Lobe, J. Filmus Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling Cancer Res 65 2005 6245 6254
120. I. Stigliano, L. Puricelli, J. Filmus Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation Breast Cancer Res Treat 114 2009 251 262
121. H. Yamamoto, F. Itoh, Y. Adachi Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma Gastroenterology 112 1997 1290 1296
122. M.G. Peters, E. Farías, L. Colombo, J. Filmus, L. Puricelli, E. Bal de Kier Joffé Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model Breast Cancer Res Treat 80 2003 221 232
123. Y. Koyama, H. Naruo, Y. Yoshitomi Matrix metalloproteinase-9 associated with heparan sulphate chains of GPI-anchored cell surface proteoglycans mediates motility of murine colon adenocarcinoma cells J Biochem 143 2008 581 592
124. H.H. Song, W. Shi, J. Filmus OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2 J Biol Chem 272 1997 7574 7577
125. J.P. Lai, J.R. Chien, D.R. Moser hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling Gastroenterology 126 2004 231 248
126. J.P. Lai, D.S. Sandhu, C. Yu Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma Hepatology 47 2008 1211 1222
127. W. Cheng, C.J. Tseng, T.T. Lin Glypican-3-mediated oncogenesis involves the insulinlike growth factor-signaling pathway Carcinogenesis 29 2008 1319 1326
128. N. Akutsu, H. Yamamoto, S. Sasaki Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma World J Gastroenterol 16 2010 3521 3528
129. T. Ishiguro, M. Sugimoto, Y. Kinoshita Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer Cancer Res 68 2008 9832 9838
130. W. Piao, Y. Wang, Y. Adachi Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas Mol Cancer Ther 7 2008 1483 1493
131. L. Libbrecht, T. Severi, D. Cassiman Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasialike nodules Am J Surg Pathol 30 2006 1405 1411
132. N. Shafizadeh, L.D. Ferrell, S. Kakar Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum Mod Pathol 21 2008 1011 1018
133. D.S. Wang, H.G. Ding, Z. Li The diagnostic value of combination with GPC-3 and AFP in hepatocellular carcinomas Zhonghua Jianyan Yixue Zazhi 10 2007 1169 1171
134. H.L. Jia, Q.H. Ye, L.X. Qin Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma Clin Cancer Res 13 2007 1133 1139
135. H. Liu, P. Li, Y. Zhai Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma World J Gastroenterol 16 2010 4410 4415
136. P. Tangkijvanich, T. Chanmee, S. Komtong Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers J Gastroenterol Hepatol 25 2010 129 137
137. K. Hagihara, K. Watanabe, J. Yamaguchi Glypican-4 is an FGF2-binding heparan sulfate proteoglycans expressed in neural precursor cells Dev Dyn 219 2000 353 367
138. S. Gengrinovitch, B. Berman, G. David, L. Witte, G. Neufeld, D. Ron Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF 165 J Biol Chem 274 1999 10816 10822
139. L. Zhang, H. Liu, L. Sun, N. Li, H. Ding, J. Zheng Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study Acta Histochem 114 2012 547 552
140. S.S. Qiao, Z.Q. Cui, L. Gong Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma Hepatogastroenterology 58 2011 1718 1724
141. H. Ozkan, H. Erdal, E. Koçak Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma J Clin Lab Anal 25 2011 350 353
142. S. Ning, C. Bin, H. Na Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients Mol Biol Rep 39 2012 351 357
143. M.C. Yu, Y.S. Lee, S.E. Lin Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin Ann Surg Oncol 2011 Aug 6 [Epub ahead of print]
144. M. Capurro, I.R. Wanless, M. Sherman Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma Gastroenterology 125 2003 89 97
145. K.R. McIntire, C.L. Vogel, A. Primack, T.A. Waldmann, S.K. Kyalwazi Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma Cancer 37 1976 677 683
146. A. Riaz, R.K. Ryu, L.M. Kulik Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival J Clin Oncol 27 2009 5734 5742
147. S.L. Chan, F.K. Mo, P.J. Johnson New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy J Clin Oncol 27 2009 446 452
148. Y. Wang, Z. Shen, Z. Zhu, R. Han, M. Huai Clinical values of AFP, GPC-3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC-3 mRNA for prediction of HCC Hepat Mon 11 2011 195 199
149. D.H. Kandil, K. Cooper Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more Adv Anat Pathol 16 2009 125 129
150. H. Shirakawa, T. Kuronuma, Y. Nishimura Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer Int J Oncol 34 2009 649 656
151. S.K. Ramaiah, S. Rittling Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer Toxicol Sci 103 2008 4 13
152. S.R. Rittling, A.F. Chambers Role of osteopontin in tumour progression Br J Cancer 90 2004 1877 1881
153. M. Gotoh, M. Sakamoto, K. Kanetaka, M. Chuuma, S. Hirohashi Overexpression of osteopontin in hepatocellular carcinoma Pathol Int 52 2002 19 24
154. H.W. Pan, Y.H. Ou, S.Y. Peng Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma Cancer 98 2003 119 127
155. Q.H. Ye, L.X. Qin, M. Forgues Predicting hepatitis B viruspositive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning Nat Med 9 2003 416 423
156. J.H. Luo, B. Ren, S. Keryanov Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas Hepatology 44 2006 1012 1024
157. J. Huang, H.H. Sheng, T. Shen Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virusassociated hepatocellular carcinoma FEBS Lett 580 2006 3571 3581
158. H. Xie, J. Song, R. Du Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma Dig Liver Dis 39 2007 167 172
159. J. Kim, S.S. Ki, S.D. Lee Elevated plasma osteopontin levels in patients with hepatocellular carcinoma Am J Gastroenterol 101 2006 2051 2059
160. H. Zhang, Q.H. Ye, N. Ren The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma J Cancer Res Clin Oncol 132 2006 709 717
161. L. Zhao, T. Li, Y. Wang Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection Int J Clin Pract 62 2008 1056 1062
162. G. Chakraborty, S. Jain, R. Behera The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis Curr Mol Med 6 2006 819 830
163. H. Rangaswami, A. Bulbule, G.C. Kundu Osteopontin: role in cell signaling and cancer progression Trends Cell Biol 16 2006 79 87
164. A.B. Tuck, A.F. Chambers, A.L. Allan Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management J Cell Biochem 102 2007 859 868
165. A.C. Cook, A.F. Chambers, E.A. Turley, A.B. Tuck Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy J Biol Chem 281 2006 24381 24389
166. Y. Wu, D.T. Denhardt, S.R. Rittling Osteopontin is required for full expression of the transformed phenotype by the ras oncogene Br J Cancer 83 2000 156 163
167. C.H. Zhang, G.L. Xu, W.D. Jia Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis Int J Cancer 130 2012 2685 2692
168. M.A. Abu El Makarem, A. Abdel-Aleem, A. Ali Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma Ann Hepatol 10 2011 296 305
169. M. Mendy, R. Walton Molecular pathogenesis and early detection of hepatocellular carcinoma-perspectives from West Africa Cancer Lett 286 2009 44 51
170. X. Wang, L. Chao, G. Ma, L. Chen, B. Tian, Y. Zang, J. Sun Increased expression of osteopontin in patients with triple-negative breast cancer Eur J Clin Invest 38 2008 438 446
171. Z. Hu, D. Lin, J. Yuan Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer Clin Cancer Res 11 2005 4646 4652
172. A. Celetti, D. Testa, S. Staibano Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness Clin Cancer Res 11 2005 8019 8027
173. D. Coppola, M. Szabo, D. Boulware Correlation of osteopontin protein expression and pathological stage across a wide variety of tumour histologies Clin Cancer Res 10 2004 184 190
174. J. Kim, S.S. Ki, S.D. Lee Elevated plasma osteopontin levels in patients with hepatocellular carcinoma Am J Gastroenterol 101 2006 2051 2059
175. M. Soresi, C. Magliarisi, P. Campagna Usefulness of a-fetoprotein in the diagnosis of hepatocellular carcinoma Anticancer Res 23 2003 1747 1753
176. P.J. Johnson The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma Clin Liver Dis 5 2001 145 159
177. R.X. Chen, Y.H. Xia, J.F. Cui, T.C. Xue, S.L. Ye Osteopontin, a single marker for predicting the prognosis of patients with tumour-node-metastasis stage I hepatocellular carcinoma after surgical resection J Gastroenterol Hepatol 25 2010 1435 1442
178. H. Xie, J. Song, R. Du, T.C. Xue, S.L. Ye Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma Dig Liver Dis 39 2007 167 172
179. F. Trevisani, P.E. D'Intino, A.M. Morselli-Labate Serum alphafetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status J Hepatol 34 2001 570 575
180. M. Gambarin-Gelwan, D.C. Wolf, R. Shapiro, M.E. Schwartz, A.D. Min Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation Am J Gastroenterol 95 2000 1535 1538
181. R.P. Singh, R. Patarca, J. Schwartz, P. Singh, H. Cantor Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo J Exp Med 171 1990 1931 1942
182. S. Ashkar, G.F. Weber, V. Panoutsakopoulou Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity Science 287 2000 860 864
183. S.K. Ramaiah, S. Rittling Role of osteopontin in regulating hepatic inflammatory responses and toxic liver injury Expert Opin Drug Metab Toxicol 3 2007 519 526
184. H. Zhang, Q.H. Ye, N. Ren The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma J Cancer Res Clin Oncol 132 2006 709 717
185. S. Shang, A. Plymoth, S. Ge Identification of osteopontin as a novel marker for early hepatocellular carcinoma Hepatology 55 2012 483 490
186. Y. Suminami, F. Kishi, K. Sekiguchi, H. Kato Squamous cell carcinoma antigen is a new member of the serine protease inhibitors Biochem Biophys Res Commun 181 1991 51 58
187. H. Kato, Y. Suehiro, H. Morioka Heterogeneous distribution of acidic TA-4 in cervical squamous cell carcinoma: immunohistochemical demonstration with monoclonal antibodies Jpn J Cancer Res 78 1987 1246 1250
188. G. Giannelli, F. Marinosci, C. Sgarra, L. Lupo, P. Dentico, S. Intonaci Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma Int J Cancer 10 2005 579 583
189. Y. Uemura, S.C. Pak, C. Luke Circulating serpin tumour markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells Int J Cancer 89 2000 368 377
190. P. Pontisso, F. Calabrese, L. Benvegnù Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma Br J Cancer 90 2004 833 837
191. M. Guido, T. Roskams, P. Pontisso Squamous cell carcinoma antigen in human liver carcinogenesis J Clin Pathol 61 2008 445 447
192. L. Beneduce, F. Castaldi, M. Marino Squamous cell carcinoma antigen-immunoglobulin M complex as novel biomarkers for hepatocellular carcinoma Cancer 103 2005 2558 2565
193. P. Pontisso, S. Quarta, C. Caberlotto Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma Int J Cancer 119 2006 735 740
194. A. Biasiolo, L. Chemello, S. Quarta Monitoring SCCAIgM complexes in serum predicts liver disease progression in patients with chronic hepatitis J Viral Hepatol 15 2008 246 249
195. S.S. Schneider, K.E. Schick, E. Fish A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene Proc Natl Acad Sci U S A 92 1995 3147 3151
196. Y. Suminami, S. Nagashima, N.L. Vujanovic, K. Hirabayashi, H. Kato, T.L. Whiteside Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen Br J Cancer 82 2000 981 989
197. Y. Suminami, N. Shigeki, A. Murakami Suppression of a squamous cell carcinoma (SCC)-related serpin, SCC antigen, inhibits tumour growth with increased intratumoural infiltration of killer cells Cancer Res 61 2001 1760 1780
198. G.H. Haidon, P.C. Hayes Screening for hepatocellular carcinoma Eur J Gastroenterol Hepatol 8 1996 856 860
199. Y. Deugnier, V. David, P. Bressot Serum a-L-fucosidase: a new marker for the diagnosis of primary hepatic carcinoma? Hepatology 4 1984 889 892
200. G. Leray, Y. Deugnier, A.M. Jouanolle Biochemical aspects of a-L-fucosidase in hepatocellular carcinoma Hepatology 9 1989 249 252
201. M.G. Giardina, M. Matarazzo, A. Varriale, R. Morante, A. Napoli, R. Martino Serum alpha-L-fucosidase A useful marker in the diagnosis of hepatocellular carcinoma Cancer 70 1992 1044 1048
202. H. Ishizuka, T. Nakayama, S. Matsuoka Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity Intern Med 38 1999 927 931
203. L.J. Deftos Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumour marker Endocr Rev 12 1991 181 187
204. N. Leone, R. Pellicano, F. Brunello, M. Rizzetto, A. Ponzetto Elevated serum chromogranin A in patients with hepatocellular carcinoma Clin Exp Med 2 2002 119 123
205. S. Ranno, M. Motta, E. Rampello, C. Risino, E. Bennati, M. Malaguarnera The chromogranin-A(CgA) in prostate cancer Arch Gerontol Geriatr 43 2006 117 126
206. M. Malaguarnera, E. Cristaldi, L. Cammalleri Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer Arch Gerontol Geriatr 48 2009 213 217
207. A. Spadaro, A. Ajello, C. Morace Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits World J Gastroenterol 11 2005 1987 1990
208. M. Malaguarnera, M. Vacante, R. Fichera, A. Cappellani, E. Cristaldi, M. Motta Chromogranin A (CgA) serum level as a marker of progression in hepatocellular carcinoma (HCC) of elderly patients Arch Gerontol Geriatr 51 2010 81 85
209. E. Wilander, M. Lundqvist, K. Oberg Gastrointestinal carcinoid tumours Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects Prog Histochem Cytochem 19 1989 1 88
210. R.J. Hsiao, R.J. Parmer, M.A. Takiyyuddin, D.T. O'Connor Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma Medicine 70 1991 33 45
211. G. Bertino, A.M. Ardiri, P. Boemi Some patients with HCC havent't abnormal des-gamma-carboxy prothrombin and alpha-fetoprotein levels" Panminerva Medica 51 2009 133 134